{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:22Z","timestamp":1772120062352,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40268-021-00358-z","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T04:04:00Z","timestamp":1628136240000},"page":"371-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6437","authenticated-orcid":false,"given":"Rosanne","family":"Sprute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pauls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Pauls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"10289","key":"358_CR1","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","volume":"397","author":"RH Shaw","year":"2021","unstructured":"Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043\u20136.","journal-title":"Lancet"},{"key":"358_CR2","unstructured":"German Standing Committee on Vaccination (STIKO). Mitteilung der STIKO zur COVID-19-Impfung: Impfabstand und heterologes Impfschema nach Erstimpfung mit Vaxzevria (1.7.2021). https:\/\/www.rki.de\/DE\/Content\/Kommissionen\/STIKO\/Empfehlungen\/PM_2021-07-01.html. Accessed 8 July 2021."},{"issue":"10249","key":"358_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467\u201378.","journal-title":"Lancet"},{"issue":"10269","key":"358_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"5","key":"358_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"13","key":"358_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMc2102131","volume":"384","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;384(13):1273\u20137.","journal-title":"N Engl J Med"},{"key":"358_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"358_CR8","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.jaip.2021.03.055","volume":"9","author":"CL Ramos","year":"2021","unstructured":"Ramos CL, Kelso JM. \u201cCOVID Arm\u201d: very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021;9:2480\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"358_CR9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","volume":"7","author":"CA Stone Jr","year":"2019","unstructured":"Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-40.e8.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"358_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/vaccines9030221","volume":"9","author":"NG Kounis","year":"2021","unstructured":"Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel). 2021;9(3):221.","journal-title":"Vaccines (Basel)."},{"issue":"6","key":"358_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jamadermatol.2021.1214","volume":"157","author":"MS Johnston","year":"2021","unstructured":"Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021;157(6):716\u201320.","journal-title":"JAMA Dermatol"},{"issue":"8960","key":"358_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(95)90963-X","volume":"345","author":"WB Shelley","year":"1995","unstructured":"Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8960):1312\u20133.","journal-title":"Lancet"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00358-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00358-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00358-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:24:52Z","timestamp":1637198692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00358-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00358-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-464753\/v1","asserted-by":"object"}]},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"15 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no specific funding for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RS, SS, MP, and WP have nothing to disclose. OAC reports grants and personal fees from Actelion, personal fees from Allecra Therapeutics, personal fees from Al-Jazeera Pharmaceuticals, grants and personal fees from Amplyx, grants and personal fees from Astellas, grants and personal fees from Basilea, personal fees from Biosys, grants and personal fees from Cidara, grants and personal fees from Da Volterra, personal fees from Entasis, grants and personal fees from F2G, grants and personal fees from Gilead, personal fees from Grupo Biotoscana, personal fees from IQVIA, grants from Janssen, personal fees from Matinas, grants from Medicines Company, grants and personal fees from MedPace, grants from Melinta Therapeutics, personal fees from Menarini, grants and personal fees from Merck\/MSD, personal fees from Mylan, personal fees from Nabriva, personal fees from Noxxon, personal fees from Octapharma, personal fees from Paratek, grants and personal fees from Pfizer, personal fees from PSI, personal fees from Roche Diagnostics, grants and personal fees from Scynexis, personal fees from Shionogi, grants from DFG, German Research Foundation, grants from German Federal Ministry of Research and Education, and grants from Immunic, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The patient gave her permission to use clinical information and photographs in the publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analysed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RS drafted the initial version of the manuscript, prepared the figure, and reviewed and approved the final version of the manuscript. SS contributed to manuscript preparation and reviewed and approved the final version of the manuscript. MP provided the case description and photographs and reviewed and approved the final version of the manuscript. WP provided the case description and photographs and reviewed and approved the final version of the manuscript. OAC conceived the study idea and reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}